Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus

References

• Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007;30:246–250.
   PubMed Web of Science ®Google Scholar
• Di Benedetto A, Russo GT, Corrado F, Di Cesare E, Alessi E, Nicocia G, D'Anna R, Cucinotta D. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 2005;28:34–38.
   PubMedGoogle Scholar
• Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005;90:3983–3988.
   PubMed Web of Science ®Google Scholar
• Negrato CA, Jovanovic L, Tambascia MA, Calderon IP, Geloneze B, Dias A. Mild gestational hyperglycaemia as a risk factor for metabolic syndrome in pregnancy and adverse perinatal outcomes. Diabetes Metab Res Rev 2008;24:324–330.
   PubMedGoogle Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
   PubMed Web of Science ®Google Scholar
• Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta 2006;1761:1359–1372.
   PubMed Web of Science ®Google Scholar
• Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987;262:4215–4222.
   PubMed Web of Science ®Google Scholar
• Kudolo GB, Bressler P, DeFronzo RA. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal 1997;17:97–113.
   PubMedGoogle Scholar
• Serban M, Tanaseanu C, Kosaka T, Vidulescu C, Stoian I, Marta DS, da Matta MF, Neves R, Tibiriça E. Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus. J Cell Mol Med 2002;6:643–647.
   PubMedGoogle Scholar
• Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2005;72:203–209.
   PubMedGoogle Scholar
• 1979 National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–1057.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Educational Program 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
   PubMedGoogle Scholar
• Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Aarsman AJ, Neys FW, Van den Bosch H. Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activating-factor acetylhydrolase. Eur J Biochem 1991;200:187–193.
   PubMedGoogle Scholar
• Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R, et al Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2009;85:61–68.
   PubMedGoogle Scholar
• Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: catalytic characteristics and relation to the monocyte derived enzyme. Artherioscler Thromb Vasc Biol 1995;15:1764–1773.
   PubMed Web of Science ®Google Scholar
• Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, et al Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low density lipoprotein: studies using a novel inhibitor. Biochem J 1999;338:479–487.
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetyhydolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413–419.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlation between plasma plateletactivating factor (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000;150:209–216.
   PubMedGoogle Scholar
• Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 2003;44:1381–1386.
   PubMedGoogle Scholar
• Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Böhm BO, Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980–987.
   PubMed Web of Science ®Google Scholar
• Howard KM, Miller JE, Miwa M, Olson MS. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem 1997;272:27543–27548.
   PubMedGoogle Scholar
• Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret plateletactivating factor acetylhydrolase. J Biol Chem 1990;265:9682–9687.
   PubMed Web of Science ®Google Scholar
• Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, Mc Intyre TM, Du BN, Fagelman AM, Berliner JA. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774–782.
   PubMed Web of Science ®Google Scholar
• Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423–436.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Satoh K, Imaizumi T. Activity of platelet-activating factor acetylhydrolase exists in red cell membrane. Am J Hematol 1992;40:61–63.
   PubMedGoogle Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946–951.
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27:1427–1432.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborwski JV, Rager JR, Boudreaux MY, Edmndowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454–5461.
   PubMed Web of Science ®Google Scholar
• Jousilahti P, Rastenyte D, Tuomilehto J. Serum g-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000;31:1851–1855.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596–1600.
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
   PubMed Web of Science ®Google Scholar